Strs Ohio increased its stake in Iradimed Corp (NASDAQ:IRMD) by 14.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,700 shares of the medical equipment provider’s stock after purchasing an additional 2,367 shares during the quarter. Strs Ohio owned about 0.17% of Iradimed worth $457,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in Iradimed by 44.1% in the third quarter. BlackRock Inc. now owns 330,441 shares of the medical equipment provider’s stock worth $12,276,000 after purchasing an additional 101,088 shares during the period. Vanguard Group Inc raised its position in Iradimed by 19.7% in the third quarter. Vanguard Group Inc now owns 250,298 shares of the medical equipment provider’s stock worth $9,298,000 after acquiring an additional 41,184 shares in the last quarter. Vanguard Group Inc. raised its position in Iradimed by 19.7% in the third quarter. Vanguard Group Inc. now owns 250,298 shares of the medical equipment provider’s stock worth $9,298,000 after acquiring an additional 41,184 shares in the last quarter. Renaissance Technologies LLC raised its position in Iradimed by 69.5% in the third quarter. Renaissance Technologies LLC now owns 198,700 shares of the medical equipment provider’s stock worth $7,382,000 after acquiring an additional 81,500 shares in the last quarter. Finally, Navellier & Associates Inc raised its position in Iradimed by 24.7% in the fourth quarter. Navellier & Associates Inc now owns 116,711 shares of the medical equipment provider’s stock worth $2,855,000 after acquiring an additional 23,127 shares in the last quarter. 21.33% of the stock is owned by institutional investors and hedge funds.

Shares of Iradimed stock opened at $27.57 on Tuesday. Iradimed Corp has a 52 week low of $12.51 and a 52 week high of $38.78. The stock has a market capitalization of $307.46 million, a price-to-earnings ratio of 64.12 and a beta of 1.85.

Iradimed (NASDAQ:IRMD) last issued its quarterly earnings results on Wednesday, February 6th. The medical equipment provider reported $0.14 EPS for the quarter, topping the consensus estimate of $0.13 by $0.01. Iradimed had a net margin of 20.71% and a return on equity of 14.26%. The firm had revenue of $8.34 million for the quarter, compared to analysts’ expectations of $8.19 million. On average, equities analysts anticipate that Iradimed Corp will post 0.62 EPS for the current year.

Several equities research analysts have commented on IRMD shares. Zacks Investment Research upgraded shares of Iradimed from a “hold” rating to a “strong-buy” rating and set a $30.00 price target on the stock in a research report on Tuesday, November 6th. ValuEngine cut shares of Iradimed from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 10th. Finally, BidaskClub upgraded shares of Iradimed from a “hold” rating to a “buy” rating in a research report on Tuesday, November 27th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $33.00.

COPYRIGHT VIOLATION NOTICE: “Iradimed Corp (IRMD) Shares Bought by Strs Ohio” was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2019/02/12/iradimed-corp-irmd-shares-bought-by-strs-ohio.html.

About Iradimed

IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name.

Read More: Capital Gains

Institutional Ownership by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.